Paper Details

  1. Home
  2. Paper Details

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.

Author: BaiYuxian, CaoPeiguo, ChenDonghui, ChenHaihui, ChenZhen-Dong, ChengYing, DengYanhong, FanSonghua, GuoWeijian, HuaYe, LiJin, LiWei, LiuTianshu, MaDong, PanHongming, QinShukui, ShenLin, ShuYongqian, SuWeiguo, SunSanyuan, WangHongbing, WangJiejun, WangShubin, WuChangping, XuJianming, XuNong, XuRui-Hua, YangLei, YuZhuang, YuanYing, ZhongHaijun, ZhouJianfeng

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Oral fruquintinib significantly increased overall survival in Chinese patients with metastatic colorectal cancer who had tumor progression following at least two prior chemotherapy regimens. Further research is needed to assess its efficacy outside of China.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: Patients with metastatic colorectal cancer (CRC) have limited effective and tolerable treatment options. OBJECTIVE: To evaluate the efficacy and safety of oral fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, as third-line or later therapy in patients with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6583690/

データ提供：米国国立医学図書館（NLM）

Fruquintinib: A New Hope for Metastatic Colorectal Cancer

The

oncology

landscape is always changing, seeking new and effective treatments for

cancer

. This study investigates the efficacy and safety of

fruquintinib

, a

vascular endothelial growth factor receptor

(VEGFR) inhibitor, for treating patients with

metastatic colorectal cancer

(CRC) who have progressed after at least two lines of chemotherapy.

Fruquintinib: A Potential Life-Extending Treatment

The study found that fruquintinib significantly prolonged overall survival compared to placebo in patients with metastatic CRC. The researchers also observed a significant improvement in progression-free survival and disease control rate with fruquintinib. These findings suggest that fruquintinib can be a valuable treatment option for patients with advanced CRC, offering a potential extension of life and improvement in quality of life.

Navigating the Desert of Cancer Treatment

If you're diagnosed with metastatic CRC, it's crucial to have open and honest conversations with your oncologist about your treatment options. They can help you weigh the benefits and risks of different therapies and create a personalized plan that addresses your specific needs and preferences. Remember, just as a camel navigates the vast and unforgiving desert, you can navigate the challenges of cancer treatment with the guidance of skilled medical professionals.

Dr.Camel's Conclusion

This research offers hope for patients with metastatic CRC, demonstrating the potential of fruquintinib to prolong survival and improve quality of life. As we continue to explore new avenues in cancer treatment, we can find new ways to combat this disease and improve the lives of patients. Just as a camel finds strength in its journey through the desert, we can find resilience in the face of adversity, supported by the advancements in medical science.

Date :
  1. Date Completed 2018-07-06
  2. Date Revised 2022-07-01
Further Info :

Pubmed ID

29946728

DOI: Digital Object Identifier

PMC6583690

Related Literature

Article Analysis
・Effects of fruquintinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.